Silo Pharma, Inc. filed a Form 8-K on November 6, 2026, disclosing that it closed a private placement on that date, raising approximately $815,000 in net proceeds through the sale of common shares and pre-funded warrants to accredited investors.

Key Highlights

  • Private placement closed: The offering closed on November 6, 2026, with securities purchase agreements dated November 5, 2026.
  • Shares issued: 136,005 shares of common stock were sold at a purchase price of $1.50 per share.
  • Pre-funded warrants: Pre-funded warrants to purchase up to an aggregate of 430,661 shares of common stock were sold at $1.4999 per warrant, with a nominal exercise price of $0.0001 per share.
  • Net proceeds: The company reported expected net proceeds of approximately $815,000 after deducting placement agent fees, expenses, and estimated offering expenses.
  • Intended use of proceeds: The company disclosed it intends to use net proceeds for working capital and general corporate purposes.
  • Registration rights: The company agreed to file a registration statement for resale of the securities no later than 30 days after the Registration Rights Agreement, dated November 5, 2026.

Silo Pharma Private Placement: Shares, Pre-Funded Warrants, and Registration Commitments

According to the filing, Silo Pharma, Inc. (NASDAQ:SILO) entered into securities purchase agreements on November 5, 2026, with certain accredited investors for a private placement of common stock and pre-funded warrants. The company issued 136,005 shares of its common stock, par value $0.0001 per share, at a purchase price of $1.50 per share. In addition, the company issued pre-funded warrants to purchase up to an aggregate of 430,661 shares of common stock at a purchase price of $1.4999 per pre-funded warrant.

The filing states that the pre-funded warrants are immediately exercisable at a nominal exercise price of $0.0001 per share and remain exercisable until all warrants are exercised in full. The filing further discloses that a holder may not exercise any portion of the pre-funded warrants to the extent the purchaser would own more than 4.99% of the outstanding common stock immediately after exercise. A holder may adjust this threshold up to a maximum of 9.99%, provided that any increase requires at least 61 days' prior notice to the company.

In connection with the private placement, the company entered into a Registration Rights Agreement, also dated November 5, 2026. Under that agreement, the company disclosed it committed to preparing and filing a registration statement with the SEC to register the resale of the shares and the underlying common stock no later than 30 days after the agreement date, with effectiveness targeted within 60 days (or 90 days in the event of a "full review" by the SEC). The securities were issued in reliance on exemptions from registration under Section 4(a)(2) of the Securities Act of 1933 and Regulation D promulgated thereunder, according to the filing. The report was signed by Eric Weisblum, Chief Executive Officer.

What Was Disclosed

Silo Pharma disclosed the closing of a private placement raising approximately $815,000 in net proceeds through the sale of 136,005 common shares at $1.50 each and pre-funded warrants for up to 430,661 shares at $1.4999 each, along with an accompanying registration rights agreement.